One-dose typhoid conjugate vaccine provides lasting protection

A single dose of a typhoid conjugate vaccine provided protection for at least 4 years among children aged 9 months to 12 years enrolled in a phase 3 trial in Malawi, according to results published in The Lancet.
Against a backdrop of rising antibiotic resistance, 2-year findings from the trial reported in 2021 showed the vaccine was effective at protecting children from typhoid fever.
WHO prequalified the vaccine, Typbar-TCV (Bharat Biotech International), in 2018, making it the first typhoid conjugate vaccine (TCV), although it had not been tested in a placebo-controlled trial until the Malawi

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart